Policy & Regulation
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
29 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Tuesday that it has agreed to invest USD2bn in newly issued equity in biopharmaceutical oncolo...
Lakewood-Amedex Biotherapeutics reports positive data for clinical candidate Nu-3 in diabetic foot ulcers
29 September 2026 - Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT), a clinical-stage biotechnology company focused on advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials f...
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
29 September 2026 - BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, announced on Monday its...
Viking Therapeutics closes offerings of common stock and convertible senior notes
29 September 2026 - Clinical-stage biopharmaceutical company Viking Therapeutics Inc (Nasdaq:VKTX) announced on Monday the closing of its concurrent upsized public offerings of 9,035,714 shares of com...
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
29 September 2026 - Chinese biotechnology company Ascletis Pharma Inc (HKEX:1672) on Monday reported positive results from a randomised, double-blind, placebo-controlled 28-day proof-of-concept clinic...
4basebio announces Phase I cell therapy programme partnership with TriLink
28 September 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) reported on Monday that it is to supply clinical-grade opDNA synthetic DNA for a multinational pharmaceutical company&...